Recruitment

Recruitment Status
Completed
Estimated Enrollment
20

Inclusion Criteria

patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks
patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks

Exclusion Criteria

active Alcohol user
presence of decompensate cirrhosis
coinfection with Hepatitis A,C,D viruses or HIV
...
active Alcohol user
presence of decompensate cirrhosis
coinfection with Hepatitis A,C,D viruses or HIV
pregnancy
Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to study
breast feeding
Severe dysfunction of liver and kidney
refusing to give informed consent

Summary

Conditions
Hepatitis C Virus
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 60 years
Gender
Both males and females

Inclusion Criteria

patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks
patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks

Exclusion Criteria

active Alcohol user
presence of decompensate cirrhosis
coinfection with Hepatitis A,C,D viruses or HIV
...
active Alcohol user
presence of decompensate cirrhosis
coinfection with Hepatitis A,C,D viruses or HIV
pregnancy
Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to study
breast feeding
Severe dysfunction of liver and kidney
refusing to give informed consent

Tracking Information

NCT #
NCT02058173
Collaborators
Not Provided
Investigators
Study Chair: Kamran B Lankarani, M.D Health policy research center